Eliana Merle
Stock Analyst at UBS
(3.86)
# 671
Out of 5,109 analysts
92
Total ratings
53.73%
Success rate
9.81%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eliana Merle
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRNA Moderna | Maintains: Buy | $70 → $40 | $32.29 | +23.88% | 8 | Oct 23, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $72 → $82 | $76.40 | +7.33% | 4 | Sep 12, 2025 | |
| GOSS Gossamer Bio | Upgrades: Buy | $1.25 → $9 | $3.29 | +173.97% | 3 | Sep 10, 2025 | |
| ALT Altimmune | Maintains: Buy | $26 → $24 | $4.00 | +500.00% | 2 | Aug 13, 2025 | |
| RAPT RAPT Therapeutics | Maintains: Neutral | $8 → $9 | $35.40 | -74.58% | 4 | Aug 12, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $458 → $523 | $602.21 | -13.15% | 5 | Aug 12, 2025 | |
| ANAB AnaptysBio | Maintains: Neutral | $18 → $20 | $50.04 | -60.03% | 5 | Aug 12, 2025 | |
| ASND Ascendis Pharma | Maintains: Buy | $306 → $307 | $209.23 | +46.73% | 2 | Aug 8, 2025 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $113 → $114 | $61.14 | +86.46% | 3 | Aug 5, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $403 → $550 | $398.70 | +37.95% | 3 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $45 → $12 | $22.00 | -45.45% | 1 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $8 | $2.50 | +220.00% | 1 | Jul 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $12 → $5.5 | $4.21 | +30.64% | 3 | Jun 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $74 → $21 | $12.18 | +72.41% | 6 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $70 | $83.53 | -16.20% | 3 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $44 | $24.82 | +77.28% | 8 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5 → $2.2 | $1.35 | +62.96% | 4 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $71 | $80.27 | -11.55% | 2 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $25.83 | +8.40% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $6.01 | +99.67% | 1 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $3 | $4.38 | -31.51% | 1 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $97 → $131 | $94.14 | +39.15% | 6 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3 → $5 | $27.45 | -81.79% | 3 | Apr 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $18 | $41.53 | -56.66% | 2 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $45 → $42 | $24.18 | +73.70% | 4 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $16.48 | +33.50% | 1 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $47 | $14.35 | +227.53% | 1 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $14.21 | +12.60% | 2 | May 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $192 → $134 | $32.94 | +306.80% | 3 | Aug 19, 2020 |
Moderna
Oct 23, 2025
Maintains: Buy
Price Target: $70 → $40
Current: $32.29
Upside: +23.88%
BridgeBio Pharma
Sep 12, 2025
Maintains: Buy
Price Target: $72 → $82
Current: $76.40
Upside: +7.33%
Gossamer Bio
Sep 10, 2025
Upgrades: Buy
Price Target: $1.25 → $9
Current: $3.29
Upside: +173.97%
Altimmune
Aug 13, 2025
Maintains: Buy
Price Target: $26 → $24
Current: $4.00
Upside: +500.00%
RAPT Therapeutics
Aug 12, 2025
Maintains: Neutral
Price Target: $8 → $9
Current: $35.40
Upside: -74.58%
Madrigal Pharmaceuticals
Aug 12, 2025
Maintains: Buy
Price Target: $458 → $523
Current: $602.21
Upside: -13.15%
AnaptysBio
Aug 12, 2025
Maintains: Neutral
Price Target: $18 → $20
Current: $50.04
Upside: -60.03%
Ascendis Pharma
Aug 8, 2025
Maintains: Buy
Price Target: $306 → $307
Current: $209.23
Upside: +46.73%
BioMarin Pharmaceutical
Aug 5, 2025
Maintains: Buy
Price Target: $113 → $114
Current: $61.14
Upside: +86.46%
Alnylam Pharmaceuticals
Aug 1, 2025
Maintains: Buy
Price Target: $403 → $550
Current: $398.70
Upside: +37.95%
Jul 21, 2025
Downgrades: Neutral
Price Target: $45 → $12
Current: $22.00
Upside: -45.45%
Jul 15, 2025
Maintains: Buy
Price Target: $4 → $8
Current: $2.50
Upside: +220.00%
Jun 26, 2025
Downgrades: Neutral
Price Target: $12 → $5.5
Current: $4.21
Upside: +30.64%
May 15, 2025
Maintains: Buy
Price Target: $74 → $21
Current: $12.18
Upside: +72.41%
May 13, 2025
Maintains: Buy
Price Target: $72 → $70
Current: $83.53
Upside: -16.20%
Apr 29, 2025
Initiates: Overweight
Price Target: $44
Current: $24.82
Upside: +77.28%
Jan 28, 2025
Maintains: Neutral
Price Target: $5 → $2.2
Current: $1.35
Upside: +62.96%
Jan 8, 2025
Maintains: Buy
Price Target: $65 → $71
Current: $80.27
Upside: -11.55%
Jan 7, 2025
Initiates: Buy
Price Target: $28
Current: $25.83
Upside: +8.40%
Nov 12, 2024
Initiates: Buy
Price Target: $12
Current: $6.01
Upside: +99.67%
Nov 12, 2024
Initiates: Neutral
Price Target: $3
Current: $4.38
Upside: -31.51%
Sep 18, 2024
Maintains: Neutral
Price Target: $97 → $131
Current: $94.14
Upside: +39.15%
Apr 4, 2024
Maintains: Neutral
Price Target: $3 → $5
Current: $27.45
Upside: -81.79%
Mar 27, 2024
Maintains: Buy
Price Target: $19 → $18
Current: $41.53
Upside: -56.66%
May 19, 2023
Maintains: Buy
Price Target: $45 → $42
Current: $24.18
Upside: +73.70%
Oct 13, 2022
Initiates: Buy
Price Target: $22
Current: $16.48
Upside: +33.50%
Jun 23, 2022
Maintains: Buy
Price Target: $51 → $47
Current: $14.35
Upside: +227.53%
May 21, 2021
Initiates: Buy
Price Target: $16
Current: $14.21
Upside: +12.60%
Aug 19, 2020
Maintains: Neutral
Price Target: $192 → $134
Current: $32.94
Upside: +306.80%